Alchemab Therapeutics has re-appointed Jane Osborn, OBE, FMEDSCI, PhD, Alchemab’s Chief Scientific Officer (CSO), to be its CEO. The OBE and Scrip's Lifetime Achievement Award winner co-founded Alchemab in 2019.
Young Kwon, outgoing CEO of Alchemab, commented:
The time is right to hand over the reins to Jane to lead the Company as CEO. Jane has been my partner in growing Alchemab and has played a central role in establishing the Company’s robust, well-tuned antibody discovery platform. I am very pleased to hand over to Jane whose scientific and organisational expertise will ensure the successful progress of Alchemab as it enters its next phase of growth.
Jane Osbourn, incoming CEO of Alchemab, commented:
I have had the great pleasure of helping to lead the Company since the beginning. We have a fantastic team who have been integral to Alchemab’s growth from a concept through to a robust and novel antibody identifying engine. With several novel targets and therapeutic antibodies in preclinical development, I am delighted to lead Alchemab as CEO through this next phase towards achieving our ultimate goal of discovering and developing ground-breaking treatments for patients.